Ignite Creation Date:
2025-12-24 @ 4:14 PM
Ignite Modification Date:
2026-01-05 @ 5:00 AM
Study NCT ID:
NCT01317966
Status:
WITHDRAWN
Last Update Posted:
2016-04-20
First Post:
2011-03-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
Sponsor:
Ming Hou
Organization:
Study Overview
Official Title:
A Multicentre Investigation of Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)
Status:
WITHDRAWN
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No eligible patients were enrolled.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Incritop
Brief Summary:
The purpose of this study is to determine whether Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab prednisone are effective and safe in the management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP).
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: